We find ourselves at the cutting edge of oncology innovation, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collaborations.

As such the 14^th World ADC London 2024 returns this March as a crucial touchpoint for all antibody drug conjugate developers across Europe.

This meeting is the place where innovation meets collaboration to drive antibody-drug conjugates forward and transform cancer therapy as we know it. Uniting 600+ industry experts and ADC newcomers, this is a conversation you can’t afford to miss.

Take a look at the full agenda here.

Embark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle.

Here are some of the leading minds sharing translatable lessons to advance your pipeline including:

1. Astrid Clarke, Director, Head of Early-Stage IND to Medicine Research,Seagen
2. Colm Reddington, Director- Global Regulatory, Chemistry, Manufacturing & Control, AstraZeneca
3. Daniel Milano, Senior Director, Process Development, ImmunoGen
4. Dhiraj Gambhire, Executive Director – Global Clinical Lead, Enhertu, Breast & Medical, Daiichi Sankyo
5. Emmett Scmidtt, Vice President, Lead External- Collaborations Project Team Global Clinical Development, Merck & Co
6. Gerold Meindhart, Vice President, Asset & Portfolio Management, Daiichi Sankyo
7. Ian Andrews, Senior Manager, Strategic External Development, GlaxoSmithKline
8. Kurt Pike, Senior Director, External Innovation, Janssen
9. Larisa Stone, Clinical Development Director, Gilead
10. Lolke deHaan, Vice President, Toxicology, ADC Therapeutics
11. Mike Liao, Global Clinical Pharmacology Lead, Genentech
12. Venkatesh Pilla Reddy, Senior Director, Global PKPD & Pharmacometrics, Eli Lilly

See the full speaker faculty and session details here.

Whether you are pioneering ADC discoveries, accelerating your conjugate through preclinical and clinical development, or optimising your CMC efforts, this is your chance to ahead of the curve with the high-quality and invaluable guidance of the supportive ADC community.